LAS 41007Alternative Names: LAS41007
Latest Information Update: 04 Nov 2018
Price : $50 *
At a glance
- Originator Almirall S.A.
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Actinic keratosis
Most Recent Events
- 30 Jul 2012 Discontinued - Phase-III for Actinic keratosis in Germany (Topical)
- 23 Jul 2012 Almirall completes a phase III trial in Actinic keratosis in Germany (NCT01265602)
- 30 Nov 2010 Phase-III clinical trials in Actinic keratosis in Germany (Topical)